Elite Pharmaceuticals (ELTP) 10-K2019 FY Annual report

Filed: 21 Jun 19, 4:31pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Adderall, ADHD, advent, Amneal, amphetamine, andJune, antibiotic, AscendMethadone, Aspartate, attainment, Aurobindo, Azar, behavior, benchmark, card, catalyst, China, Chinese, Citizen, clarification, cloud, CMS, codeine, codeveloper, codified, combat, Dantrolene, deadline, Dextroamphetamine, disaggregated, disaster, Disorder, distinct, distract, drain, encouraging, Endo, engender, epidemic, excessive, expedient, explain, explanatory, familiarity, feasibility, grantor, hour, housing, Hydroxzine, Hyperactivity, inAccounting, inconsequential, inItem, IQVIA, irrelevance, Lannett, left, lot, Loxapine, loyalty, Mallinckrodt, medium, Mexico, mild, milligram, morphine, Narcolepsy, Nonemployee, Northern, onform, onMarch, overcome, overcoming, PAS, phosphate, pipe, PPACA, PPCA, prompting, prone, QVIA, rationing, reconciling, recordkeeping, Recovery, rescheduled, retaliatory, Rulemaking, Saccharate, salt, seeded, sensitivity, Sodium, Southern, statute, Stewardship, storm, strongly, substitution, Subtopic, Sulfate, sweeping, tariff, TCJA, therapy, toexhibit, Tylenol, unconstitutional, unfilled, unremediated, upfront, USTR, vandalism, variation

Removed: Acura, adult, agreeing, Allergen, anticipating, antihistamine, await, bankruptcy, Biotime, brompheniramine, CBE, ceased, Celgene, composite, constituting, core, custom, decongestant, delivered, divested, domicile, Durect, economically, encompassing, enhancement, expedited, FDCA, graph, Hong, Impax, Indigo, informed, insolvency, Jerry, Kong, lab, lawfully, liquidating, list, LLCE, MKT, Monograph, NE, peer, placement, principle, pseudoephedrine, reassessed, Reg, reinvestment, relevance, remained, replace, retire, Room, Russell, Street, Subramanian, succeeding, superseded, Supplementary, tangible, Treppel, unaudited, undelivered, undue, unregistered, Unsecured, Valeant, Veerappan, VGS, Willstar

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated ELTP transcripts

ELTP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Elite Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended March 31, 2019 filed with Securities and Exchange Commission (the “Report”), I, Carter J. Ward, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	1.	The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

Date: June 21, 2019	/s/ Carter Ward
	Carter J. Ward, Chief Financial Officer

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

A signed original of this written statement required by Section 906 has been provided to Elite Pharmaceuticals, Inc. and will be retained by Elite Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.